Zibo Zhao

This study identifies POU2AF2 as a lineage-specific dependency in DLBCL, showing it coactivates POU2F2 to sustain malignant transcriptional networks and innate-like B-cell identity.

The paper identifies and characterizes FCD-11, a first-in-class COMPASS inhibitor that reduces tumor size and extends survival in breast cancer models.